Free Trial

Blueprint Medicines (BPMC) Competitors

Blueprint Medicines logo
$129.30 -0.03 (-0.02%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$129.30 0.00 (0.00%)
As of 07/11/2025 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BPMC vs. BNTX, ONC, TEVA, INSM, SMMT, ITCI, GMAB, RDY, MRNA, and RGC

Should you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include BioNTech (BNTX), BeOne Medicines (ONC), Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry.

Blueprint Medicines vs. Its Competitors

BioNTech (NASDAQ:BNTX) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

BioNTech has a net margin of -27.37% compared to Blueprint Medicines' net margin of -27.70%. BioNTech's return on equity of -3.94% beat Blueprint Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
BioNTech-27.37% -3.94% -3.41%
Blueprint Medicines -27.70%-64.60%-17.22%

BioNTech currently has a consensus price target of $137.91, suggesting a potential upside of 22.17%. Blueprint Medicines has a consensus price target of $128.25, suggesting a potential downside of 0.81%. Given BioNTech's stronger consensus rating and higher probable upside, analysts plainly believe BioNTech is more favorable than Blueprint Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNTech
0 Sell rating(s)
4 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.83
Blueprint Medicines
0 Sell rating(s)
17 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.24

In the previous week, BioNTech had 2 more articles in the media than Blueprint Medicines. MarketBeat recorded 11 mentions for BioNTech and 9 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 1.23 beat BioNTech's score of 0.89 indicating that Blueprint Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioNTech
6 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Blueprint Medicines
6 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Blueprint Medicines has lower revenue, but higher earnings than BioNTech. Blueprint Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNTech$2.98B9.11-$719.92M-$3.40-33.20
Blueprint Medicines$508.82M16.41-$67.09M-$2.47-52.35

15.5% of BioNTech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioNTech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

Summary

BioNTech beats Blueprint Medicines on 12 of the 16 factors compared between the two stocks.

Get Blueprint Medicines News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPMC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPMC vs. The Competition

MetricBlueprint MedicinesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$8.35B$2.99B$5.60B$9.11B
Dividend YieldN/A2.39%5.24%4.02%
P/E Ratio-52.3520.5827.9620.25
Price / Sales16.41292.00430.8999.65
Price / CashN/A42.8637.4658.16
Price / Book27.517.638.045.49
Net Income-$67.09M-$55.05M$3.18B$250.27M
7 Day Performance0.80%8.39%3.63%4.75%
1 Month Performance0.85%5.35%4.04%7.64%
1 Year Performance9.78%1.95%29.55%16.34%

Blueprint Medicines Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPMC
Blueprint Medicines
1.0898 of 5 stars
$129.30
0.0%
$128.25
-0.8%
+9.8%$8.35B$508.82M-52.35640Positive News
Insider Trade
High Trading Volume
BNTX
BioNTech
1.4923 of 5 stars
$110.05
+0.0%
$137.86
+25.3%
+33.3%$26.45B$2.98B-32.376,772News Coverage
Analyst Forecast
ONC
BeOne Medicines
3.446 of 5 stars
$240.99
-1.8%
$320.67
+33.1%
N/A$26.41B$4.18B-64.7811,000Trending News
Analyst Downgrade
Insider Trade
TEVA
Teva Pharmaceutical Industries
4.1288 of 5 stars
$16.84
-1.0%
$24.13
+43.3%
-4.2%$19.31B$16.54B-14.6436,830Positive News
INSM
Insmed
4.3574 of 5 stars
$96.95
-0.9%
$106.80
+10.2%
+27.5%$18.39B$363.71M-16.291,271Analyst Forecast
Insider Trade
SMMT
Summit Therapeutics
2.8189 of 5 stars
$22.61
-7.9%
$34.67
+53.3%
+188.0%$16.79B$700K-66.50110
ITCI
Intra-Cellular Therapies
0.6601 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
4.101 of 5 stars
$20.52
+1.1%
$37.60
+83.2%
-18.4%$13.16B$3.12B11.662,682Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.7589 of 5 stars
$15.08
flat
$16.95
+12.4%
-7.9%$12.59B$3.81B22.8527,811
MRNA
Moderna
4.3068 of 5 stars
$29.90
-1.9%
$46.61
+55.9%
-72.6%$11.56B$3.24B-3.425,800Trending News
RGC
Regencell Bioscience
0.3677 of 5 stars
$18.43
-19.8%
N/AN/A$11.37BN/A0.0010Gap Down

Related Companies and Tools


This page (NASDAQ:BPMC) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners